Therapeutic Approach

Archive: 2013

Using Galacto-Oligosaccharides to Improve Lactose Tolerance: Food Technology

A link to the article can be found here: link

Leave Your Comments »

Ritter Pharmaceuticals’ Study Shows That Altering The Intestinal Microbiome May Offer An Effective Treatment for Lactose Intolerance

Data presented at New York Academy of Sciences LOS ANGELES, Calif., June 12, 2013 — Ritter Pharmaceuticals announced that data from its Phase 2 clinical study of RP-G28, in patients with lactose intolerance demonstrated the agent’s ability to alter the composition of microbes in patient’s intestines. The work was presented at the New York Academy […]

Leave Your Comments »

Andrew Ritter Named Finalist in LA Business Journal’s Annual Healthcare Leadership Awards

A copy of the article can be found here: LOS ANGELES, Calif., April 23, 2013 — Andrew Ritter, president and CEO of Ritter Pharmaceuticals, Inc., was selected as a finalist for the third annual Healthcare Leadership Awards recently presented by The Los Angeles Business Journal.   Andrew has been at the forefront of researching the physiological […]

Leave Your Comments »

Patient Survey: More than 80% Forced to Change Lifestyles Due to Lactose Intolerance

Condition Significantly Affects Quality of Life – LOS ANGELES, Calif., April 17, 2013 – According to a recent survey, eight out of ten people with mild to severe Lactose Intolerance (LI) are compelled to modify their diets and other daily activities in an effort to manage or forestall the symptoms of their disorder. Patients report […]

Leave Your Comments »

Ritter Pharmaceuticals Encouraged by Meeting with FDA: Feedback Provides Clarity for Clinical Development Plans

LOS ANGELES, CALIF., MARCH 20, 2013 — Ritter Pharmaceuticals today reported that it is preparing to move forward with the design and implementation of the next stage of clinical trials to advance the development of RP-G28, the first therapeutic agent aimed at treating Lactose Intolerance.  Company representatives recently met with teams from the FDA to […]

Leave Your Comments »

Ritter Pharmaceuticals Names Larry Good, M.D. Chief Medical Officer

LOS ANGELES, CA. – February 13, 2013 – Ritter Pharmaceuticals, Inc. today announced the appointment of Larry I. Good, M.D., F.A.C.G. to the position of Chief Medical Officer.  Dr. Good’s extensive experience as a practicing gastroenterologist has strengthened the company’s mission to develop novel treatments for lactose intolerance and other gastrointestinal disorders. Ritter expects to design […]

Leave Your Comments »

Survey: 75% of People with Lactose Intolerance Avoid Dairy Foods

May Result in Nutritional Deficit, Increased Risk to Long-term Health Los Angeles, Calif., January 30, 2013 – –  A recent survey of patients with Lactose Intolerance revealed that more than three fourths of them reduce or eliminate dairy from their diets as the primary means of “managing” their symptoms.  What’s more, a majority (56%) of […]

Leave Your Comments »

Lactose Intolerance: Major Unmet Medical Need

Ritter Pharmaceuticals Encouraged by Phase 2 Results with First -in-Class Lactose Intolerance Treatment LOS ANGELES, Calif. – January  7, 2012 —  Nearly 40 million Americans are lactose intolerant and must significantly limit – or avoid – milk and dairy products, or suffer with embarrassing and debilitating gastrointestinal pain.  Despite the availability of lactose-free food options […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD